Cargando…
Update on the treatment of narcolepsy: clinical efficacy of pitolisant
Narcolepsy is a neurological disease that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness (EDS). In 60–70% of individuals with narcolepsy, it is also characterized by cataplexy or a sudden loss of muscle tone that is triggered by positive or negative emotions. Nar...
Autor principal: | Calik, Michael W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414617/ https://www.ncbi.nlm.nih.gov/pubmed/28490912 http://dx.doi.org/10.2147/NSS.S103462 |
Ejemplares similares
-
Efficacy of Pitolisant on the Treatment of Narcolepsy: A Systematic Review
por: Fabara, Stephanie P, et al.
Publicado: (2021) -
Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy
por: Romigi, Andrea, et al.
Publicado: (2018) -
Pitolisant to Treat Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy: Rationale and Clinical Utility
por: Guevarra, Jay T, et al.
Publicado: (2020) -
Orgasmolepsy in Narcolepsy Type 1 Responsive to Pitolisant: A Case Report
por: Pellitteri, Gaia, et al.
Publicado: (2020) -
Comparison of modafinil and pitolisant in narcolepsy: a non-inferiority meta-analytical approach
por: Lehert, Philippe, et al.
Publicado: (2020)